Company intelligence / Profile preview
CellTherX
Houston or Dallas area, Texas, United Statescelltherx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CellTherX has developed proprietary Microsurfacing technology that enhances the efficacy of reconstructive tissue grafts by increasing their surface area, promoting better cellular integration, faster healing, and improved outcomes. Their IP is currently licensed in the dental market as Cytoplast Microderm. A recent clinical study led by Dr. Michael McGuire confirmed benefits over traditional allografts; publication is expected in late 2024.
- Therapeutic areas
- DermatologyOther
- Modalities
- Regenerative tissue graftsAcellular dermal matrixDecellularized amnion/chorion tissue
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Osteogenics Biomedical (licensee/distribution partner for dental market)
Beyond the preview
Go deeper on CellTherX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellTherX.